• Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$3.62
▲ +0.04 (1.12%)

This chart shows the closing price for XBIT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New XBiotech Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for XBIT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for XBIT

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for XBiotech in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $3.62.

This chart shows the closing price for XBIT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in XBiotech. This rating has held steady since March 2021, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/10/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/9/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/7/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/5/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/5/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/4/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/2/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/2/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/7/2020Piper SandlerLower TargetOverweight$28.00 ➝ $18.00Low
12/11/2019Piper Jaffray CompaniesBoost TargetOverweight$16.00 ➝ $28.00Low
11/13/2019Piper Jaffray CompaniesReiterated RatingOverweight$13.00 ➝ $16.00High
6/14/2019Piper Jaffray CompaniesInitiated CoverageOverweight$13.00Low
(Data available from 10/2/2017 forward)

News Sentiment Rating

0.38 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/6/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/5/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
5/5/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/4/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
7/4/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/3/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/2/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
10/2/2022

Current Sentiment

  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Negative

  • No negative mentions tracked during this time.
XBiotech logo
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation, and True Human COVID-19 therapy for treating the COVID-19 mutant virus. The company was incorporated in 2005 and is headquartered in Austin, Texas.
Read More

Today's Range

Now: $3.62
Low: $3.56
High: $3.67

50 Day Range

MA: $4.47
Low: $3.58
High: $5.29

52 Week Range

Now: $3.62
Low: $3.55
High: $16.47

Volume

38,980 shs

Average Volume

40,366 shs

Market Capitalization

$110.19 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.3

Frequently Asked Questions

What sell-side analysts currently cover shares of XBiotech?

The following Wall Street analysts have issued stock ratings on XBiotech in the last twelve months: StockNews.com, and TheStreet.
View the latest analyst ratings for XBIT.

What is the current price target for XBiotech?

0 Wall Street analysts have set twelve-month price targets for XBiotech in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for XBiotech in the next year.
View the latest price targets for XBIT.

What is the current consensus analyst rating for XBiotech?

XBiotech currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for XBIT.

What other companies compete with XBiotech?

How do I contact XBiotech's investor relations team?

XBiotech's physical mailing address is 5217 Winnebago Ln, AUSTIN TX, 78744. The biopharmaceutical company's listed phone number is (512) 386-2900 and its investor relations email address is [email protected] The official website for XBiotech is www.xbiotech.com. Learn More about contacing XBiotech investor relations.